Linked Life Data

8878586

Source:http://linkedlifedata.com/resource/pubmed/id/8878586

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
1997-2-6
pubmed:abstractText
Single-dose and steady-state pharmacokinetics of antivirally acting hypericin (H) and pseudohypericin (PH) were studied in 13 healthy volunteers by administration of St. John's Wort extract LI 160, a plantal antidepressant. Oral administration of 250, 750, and 1,500 micrograms of H and 526, 1,578, and 3,156 micrograms of PH resulted in median peak levels in plasma (Cmax) of 1.3, 7.2, and 16.6 micrograms/liter for H and 3.4, 12.1, and 29.7 micrograms/liter for PH, respectively. The Cmax and the area under the curve values for the lowest dose were disproportionally lower than those for the higher doses. A lag time of 1.9 h for H was remarkably longer than the 0.4-h lag time for PH. Median half-lives for absorption, distribution, and elimination were 0.6, 6.0, and 43.1 h after 750 micrograms of H and 1.3, 1.4, and 24.8 h after 1,578 micrograms of PH, respectively. Fourteen-day treatment with 250 micrograms of H and 526 micrograms of PH three times a day resulted in median steady-state trough levels of 7.9 micrograms/liter for H and 4.8 micrograms/liter for PH after 7 and 4 days, respectively; the corresponding Cssmax levels were 8.8 and 8.5 micrograms/liter, respectively. Kinetic parameters after intravenous administration of Hypericum extract (115 and 38 micrograms for H and PH, respectively) in two subjects corresponded to those estimated after an oral dosage. Both H and PH were initially distributed into a central volume of 4.2 and 5.0 liter, respectively. The mean distribution volumes at steady state were 19.7 liters for H and 39.3 liters for PH, and the mean total clearance rates were 9.2 ml/min for H and 43.3 ml/min for PH. The systemic availability of H and PH from LI 160 was roughly estimated to be 14 and 21%, respectively. Treatment with Hypericum extract, even in high doses, was well tolerated.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/8878586-1283309, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878586-1310583, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878586-1377897, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878586-1576062, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878586-1665961, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878586-1739734, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878586-1888019, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878586-2548193, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878586-2839837, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878586-7343570, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878586-7568399, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878586-7678335, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878586-7740610, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878586-7991618, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878586-8178343, http://linkedlifedata.com/resource/pubmed/commentcorrection/8878586-8460933
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
40
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2087-93
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin.
pubmed:affiliation
Institute of Clinical Pharmacology, University Clinic Charité, Humboldt University of Berlin, Germany.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't